MedTrace Logo

Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients

NCT03003143 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-09-29

No results posted yet for this study

Summary

Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients

Conditions

  • Autoimmune Encephalopathy

Interventions

DRUG

Vigabatrin 500 MG

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • KON CHU, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-09-09
Completion
2020-09-09

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003143 on ClinicalTrials.gov